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Cancer results from genetic alterations that disturb the normal cooperative behavior of cells. Recent high-throughput
genomic studies of cancer cells have shown that the mutational landscape of cancer is complex and that individual
cancers may evolve through mutations in as many as 20 different cancer-associated genes. We use data published by
Sjo ¨blom et al. (2006) to develop a new mathematical model for the somatic evolution of colorectal cancers. We employ
the Wright-Fisher process for exploring the basic parameters of this evolutionary process and derive an analytical
approximation for the expected waiting time to the cancer phenotype. Our results highlight the relative importance of
selection over both the size of the cell population at risk and the mutation rate. The model predicts that the observed
genetic diversity of cancer genomes can arise under a normal mutation rate if the average selective advantage per
mutation is on the order of 1%. Increased mutation rates due to genetic instability would allow even smaller selective
advantages during tumorigenesis. The complexity of cancer progression can be understood as the result of multiple
sequential mutations, each of which has a relatively small but positive effect on net cell growth.
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Introduction
The current view of cancer is that tumorigenesis is due to
the accumulation of mutations in oncogenes, tumor suppres-
sor genes, and genetic instability genes [1]. Sequential
mutations in these genes lead to most of the hallmarks of
cancer [2]. Cancer research has beneﬁted immensely from
studies of uncommon inherited cancer syndromes that served
to highlight the importance of individual genes in tumori-
genesis [3]. Theoretical considerations have suggested that a
handful of mutations, perhaps as few as three, may be
sufﬁcient for developing colorectal cancer [4,5]. This rela-
tively small number is consistent with the standard model for
colorectal tumorigenesis based on the identiﬁcation of
mutations in well-known cancer genes [6]. However, Sjo ¨blom
et al. [7] have recently determined the sequence of 13,000
genes in colorectal cancers and found that individual tumors
contained an average of 62 nonsynonymous mutations.
Extrapolating to the entire genome, it was estimated that
individual colorectal cancers contain about 100 nonsynon-
ymous mutations and that as many as 20 of the mutated genes
in individual cancers might play a causal role in the
neoplastic process [7].
Tumors arise from a process of replication, mutation, and
selection through which a single cell acquires driver
mutations which provide a ﬁtness advantage by virtue of
enhanced replication or resistance to apoptosis [8]. Each
driver mutation thereby allows the mutant cell to go through
a wave of clonal expansion. Along with drivers, passenger
mutations, which do not confer any ﬁtness advantage, are
frequently observed. Passenger mutations arise in advanta-
geous clones and become frequent by hitchhiking. The
accumulation of ;100 mutations per cell is therefore the
result of sequential waves of clonal expansion; the observed
mutations mark the history of the cancer cell, including both
drivers and passengers.
Genetic mutations can arise either due to errors during
DNA replication or from exposure to genotoxic agents. The
normal mutation rate due to replication errors is in the range
of 10
 10 to 10
 9 per nucleotide per cell per division [9]. It is
likely that the initial steps leading to cancer arise in cells with
a normal mutation rate [10]. A normal mutation rate might
also be sufﬁcient to generate the large numbers of mutations
in cancer given the many generations that the dominant
cancer cell clone has gone through both before and after its
initiating mutation [11–13]. However, it has also been argued
that tumor cells have mutator phenotypes that accelerate the
acquisition of mutations [14].
Mathematical modeling of carcinogenesis has had a rich
history since its introduction more than 50 years ago [15–17].
The initial two-hit theory has evolved into more elaborate
models incorporating multiple hits, rate-limiting events, and
genomic instability [4,18–23]. Most models consider the stem
cell at the base of the colonic crypt as the initial target for
mutation, with the daughter cells giving rise to the adenoma
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ment [4,22].
The tumor data collected by Sjo ¨blom et al. [7] show that the
mutational patterns among colorectal cancers from different
patients are diverse. This observation indicates that there
may be many different mutational pathways that can lead to
the same cancer phenotype. In the model described below, we
assume that there are 100 potential driver genes and ask for
the expected waiting time until one cell has acquired
mutations in a given number, up to 20, of these genes. We
assume that one or two initial mutations, perhaps together
with losses or gains of large chromosomal regions [15,16], give
rise to a benign tumor (adenoma) of ;1 milligram or 10
6 cells
(Figure 1). We model the progression of this adenoma to full-
blown cancer over a period of ﬁve to 20 years [16], in which
the adenoma grows to ;1 gram, or 10
9 cells. Whether the
whole population of cells is at risk for clonal expansion or
whether a fraction of cells akin to stem cells drives growth of
the adenoma is currently a subject of debate. This is
important as cancer stem cells, as well as other factors such
as geometric constraints on the architecture of the adenoma,
may signiﬁcantly reduce the effective population size and
thereby impact the waiting time to cancer [24,25]. Note that it
is not size that distinguishes a cancer from an adenoma;
rather it is the ability of the cancer cells to invade through the
underlying basement membrane and escape from its normal
anatomical position.
We use the Wright-Fisher process [26] to model the somatic
evolution of cancer in a colonic adenoma. We assume a cell
turnover of one per day [27] and analyze the time to cancer as
a function of the population size N, the per-gene mutation
rate u, and the average selective advantage s per mutation. We
present extensive simulation results as well as analytical
approximations to the expected waiting time. The model
offers a basic understanding of how the different evolu-
tionary forces contribute to the progression of cancer.
Results
The mutation data are represented in a binary matrix of
size 35378, whose rows correspond to 35 tumor samples and
whose columns correspond to the 78 candidate cancer genes
identiﬁed by Sjo ¨blom et al. [7] (Figure 2). A non-zero entry in
cell (i, j) of this matrix indicates the presence of a mutation in
gene j of tumor i. Tumors harbor between 1 and 20 mutated
genes (mean ¼ 6.5). Most of these genes (66/78 ¼ 85%) are
mutated in at most three different tumors, resulting in highly
diverse mutational patterns among the tumors. The notable
exception are the three well-known cancer genes APC, p53,
and K-ras, which were found mutated in 24, 17, and 16
tumors, respectively. We have analyzed partial correlations
between genes, taking into account the small number of
observations and multiple comparisons. Several pairs of
genes were signiﬁcantly correlated, most of them positively,
but all correlations were weak and below 0.07 (Figure S1).
From this data analysis, we conclude that in colon cancer, a
very small number of genes are mutated in a large fraction of
tumors. However, many other genes are involved in tumor
progression, although each single gene is mutated only in a
small subset of tumors without a clear pattern emerging.
For the purpose of mathematical modeling of tumori-
genesis, we consider the presence of an adenoma. Adenoma
formation probably requires the appearance of mutations in
one or a few genes (in particular, APC) that are common to
most tumors. We assume the occurrence of all subsequent
mutations to be independent events. When any k out of d ¼
100 susceptible genes are mutated in a single cell, the cancer
phenotype is considered to be attained. The ﬁrst cells of this
type mark the onset of an invasive tumor. The Wright-Fisher
process is used to describe these evolutionary dynamics.
Despite the large population size of up to N¼10
9 cells, we can
efﬁciently compute estimates of the time to the ﬁrst
appearance of any k-fold mutant by simulation, because it
Figure 1. Schematic Representation of the Evolution of Cancer in a Colonic Adenoma
The adenoma grows from a population of 10
6 to 10
9 cells which accumulate mutations that drive phenotypic changes seen in cancer cells. Blue circles
symbolize adenoma cells prior to accumulating the additional mutations that are the subject of modeling, green indicates cells that have acquired
additional, but an insufficient number of mutations for malignancy, and red indicates cells with the number of mutations required for the cancer
phenotype.
doi:10.1371/journal.pcbi.0030225.g001
PLoS Computational Biology | www.ploscompbiol.org November 2007 | Volume 3 | Issue 11 | e225 2240
Author Summary
Cancer is a disease of multicellular organisms that is characterized
by a breakdown of cooperation between individual cells. The
progression of cancer proceeds from a single genetically altered cell
to billions of invasive cells through a series of clonal expansions.
During tumorigenesis the cancer cells undergo replication and
mutation, thereby increasing the size and invasiveness of the tumor.
Recent sequencing projects of cancer cells suggest that mutations in
up to 20 different genes might be responsible for driving an
individual tumor’s development. This insight contrasts with most
mathematical models of cancer progression, which assume that the
cancer phenotype is driven by mutations in only a few genes. We
present a new mathematical model in which tumorigenesis is driven
by mutations in many genes, most of which confer only a small
selective advantage. Specifically, the progression of a benign tumor
of the colon (adenoma) to a malignant tumor (carcinoma) is
described by a Wright-Fisher process with growing population size.
We explore the basic parameters of the model that are consistent
with observed data. We also derive an analytical formula for the
expected waiting time for the progression from benign to maligant
tumor in terms of the population size, the mutation rate, the
selective advantage, and the number of susceptible genes.
Genetic Progression of Cancersufﬁces to trace the distribution of the k þ 1 mutant error
classes in each generation. We assume a constant average
selective advantage, s, for each mutation and a per-gene
mutation rate, u. Figure 3 displays the typical behavior of this
process in a single simulation. After a short initial phase in
which the homogeneous wild-type population produces the
ﬁrst low-order mutants, a traveling wave is observed (Figure
3). Apparently, this distribution of error classes has constant
variance and travels with constant velocity toward higher-
order mutants. Thus, we expect the time until the ﬁrst k-fold
mutant appears to be linear in k. This conjecture is
substantiated by simulations for a wide range of parameters
(Figure S2) provided that mutations are advantageous (s . 0).
Within our model, the probability of developing cancer is
equated with the probability of generating at least one k-fold
mutant cell in the adenoma. For k ¼ 20, this probability as a
function of time is depicted in Figure 4. The expected time to
the development of cancer increases with decreasing cell
population size (hence the low risk of cancer associated with
very small adenomas), with decreasing selective advantage,
and with decreasing mutation rate. Thus, if the population at
risk is a small subset composed of actively replicating stem
cells, tumor progression will be slow. In contrast, an increased
mutation rate due to genetic instability speeds up this
process.
The simulations suggest that in a time frame of 5 to 15
years, cancer might develop in an adenoma of size 10
7 to 10
9
cells with a normal mutation rate of 10
 7 per gene per cell
division and a 1% selective advantage per mutation (Figure
4A). Alternatively, a higher mutation rate of 10
 5 per gene
per cell division would enable a smaller population of at-risk
cells (10
5 to 10
7) and a smaller selective advantage (0.1%) to
reach the required number of mutations in the same time
interval (Figure 4B). However, for reasonable mutation rates,
a completely neutral process (s ¼ 0) predicts waiting times
that are not consistent with the observed incidence of colon
cancer, as would be expected (Figure 4, Figure S2).
Figure 5 generalizes these ﬁndings to different values of k
by partitioning the parameter space of the model into regions
of identical evolutionary outcomes. Each curve deﬁnes an
instance of the Wright-Fisher process that results in a 10%
chance of developing a k-fold mutant after 3,000 generations
(or 8.2 years). These level curves deﬁne the parameter
combinations that produce similar dynamics. For example,
a small at-risk population is unlikely to generate a cancer
requiring more than ten driver gene mutations unless the
selective advantage for these mutations is large (see Dis-
cussion).
Based on the simulation results, we have derived an
analytical approximation for the expected time to cancer.
The key observation is that the distribution of error types
follows a Gaussian (Figure 3). This approach leads to the
expression
tk ¼ k
log s
ud
   2
slogðNinitNfinÞ
ð1Þ
for the expected waiting time, where k is the number of
cancer-deﬁning genes, d is the number of susceptible genes, u
is the mutation rate, s the average selective advantage, and
Ninit and Nﬁn are the initial and ﬁnal population sizes of the
polyp, respectively (see Materials and Methods). The approx-
imation is linear in k (Figure S2) and matches closely the
observed behavior of the Wright-Fisher process, as long as s .
0 (Figures 3–5). The ﬁt is analyzed quantitatively in Protocol
S1. The expression for tk highlights the strong effect of the
selective advantage on tumorigenesis, and gives an explicit
tradeoff between the evolutionary forces.
Discussion
Research over the past three decades has shown that cancer
is an acquired genetic disorder [1]. The process of replication,
mutation, and selection eventually leads to the appearance of
tumors in multicellular organisms if they live long enough.
Tumor cells accumulate many mutations in their evolu-
tionary path [7,8,28], but not all mutations play a causal role
in the evolution of the clone. If a gene is mutated in tumors
Figure 2. Mutational Patterns in 35 Late-Stage Colorectal Cancer Tumors from Sjo ¨blom et al. (2006)
Matrix rows are indexed by tumors, columns are indexed by cancer-associated genes as identified by Sjo ¨blom et al. (2006). Dark spots indicate mutated
genes. Both tumors and genes have been sorted by an increasing number of mutations. The three genes mutated most often are APC (in 24 tumors; last
column), p53 (in 17 tumors; penultimate column), and K-ras (in 16 tumors; adjacent to p53 column).
doi:10.1371/journal.pcbi.0030225.g002
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Genetic Progression of Cancerderived from different patients, it is less likely to be a
passenger and more likely to provide the cell with a selective
advantage, permitting it to expand and eventually dominate
the population. Based on this reasoning, the data in Sjo ¨blom
et al. [7] suggest that as many as ;20 driver genes are mutated
per tumor. The diverse mutational landscapes observed in
tumor cells of the same tissue origin suggest that different
mutations can have the same phenotypic effect. One plausible
explanation for this observation is that genes are organized
into intracellular pathways (signaling, metabolic, checkpoint,
etc.), and the disturbance of these pathways drives tumori-
genesis. Within each cell, every information transfer cascade
requires functional proteins that are the products of distinct
genes. Mutations in any one of the genes that code for
proteins in a given pathway can complement each other and
their genetic alterations can have similar phenotypic effects
[1]. This view is supported by the observation that multiple
hits in different genes of the same pathway in individual
tumors are less frequent than expected [1].
In our model, we assume that each subsequent mutation
has the same incremental effect on the ﬁtness of the cell. In
general, however, the impact of a speciﬁc mutation on the
phenotype of the cell will depend on the genetic background.
Gene interactions, or epistasis, can be positive or negative,
and they can impose constraints on the order in which
mutations accumulate [1]. In this case, the model parameter s
may be regarded as the average ﬁtness increase per mutation.
We have seen that a ﬁtness increase of 1% per mutation
may be enough for the Wright-Fisher model to generate
dynamics that are consistent with the observed time scale of
evolution from adenoma to carcinoma. However, genetic
alterations associated with the initiation of colon cancer
(such as those in APC) may have larger ﬁtness advantages than
those associated with tumor progression. The value or
distribution of the ﬁtness parameter s, which is unknown at
present, will ultimately clarify the role of selection in this
evolutionary process. We emphasize, however, that our
estimates of s are based on the assumptions of the Wright-
Fisher model. Thus, additional uncertainty in determining
the role of selection is associated with violations of these
assumptions by the biological system. Other models may lead
to different estimates of the ﬁtness associated with mutations,
depending among other factors on the number of mutations
necessary to reach the malignant phenotype and on the
timescale [29].
In another simplifying abstraction, we have deﬁned the
tumor cell by the accumulation of k ¼ 20 mutations in
different driver genes. In reality, it is unlikely that any
combination of 20 genes will induce the cancer phenotype.
Our assumption is based on the observed cancer genotypes
which fail to reveal a striking genetic signature of cancer cells.
In this respect, our model provides lower bounds on the
expected waiting time to cancer, as reaching a speciﬁc 20-fold
mutant may take signiﬁcantly longer.
These abstractions are important because all lesions begin
with a small number of neoplastic cells. The simulations in
Figure 5 show that cancers would never result from such small
numbers of cells if 20 driver mutations were required and
each mutation conferred only a small ﬁtness advantage. It is
likely that some of the early mutations (such as those in K-ras)
increase ﬁtness more than the average, allowing a small,
initiating lesion to grow into an intermediate size lesion.
Once a growth reaches this size, mutations with small ﬁtness
advantages can accumulate and eventually convert the tumor
into a cancer.
The large population size of 10
9 cells would suggest that a
Figure 3. Evolution of Cancer Modeled by the Wright-Fisher Process
The distribution of cells in the error classes N0, ..., N20 is displayed in a single simulation over a time period of 12 years after which the first cell
harboring 20 mutations appears. The total population size (dashed line) grows exponentially from 10
6 to 10
9 cells in this time period. Each cell has 100
susceptible genes, all of which are of wild-type initially. We further assumed a mutation rate of 10
 7 per gene, a 1% selective advantage per mutation,
and a turnover of 1 cell division per cell per day. Each error class has an approximately Gaussian distribution (after a short initial phase), but the
introduction of each new mutant is subject to stochastic fluctuations.
doi:10.1371/journal.pcbi.0030225.g003
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Genetic Progression of Cancerpurely deterministic approximation to the Wright-Fisher
process is reasonable. It turns out, however, that the
stochasticity associated with generating mutants of each
new type has a strong impact on the evolutionary dynamics
(see Protocol S1). Therefore, a deterministic model of
evolutionary dynamics will signiﬁcantly underestimate the
time to cancer. The closer approximation presented here
exploits the regular behavior of the system of propagating a
Gaussian distribution of error types and takes into account
stochastic effects in determining the speed of this traveling
wave. Thus, stochastic effects can play an important role even
in very large populations.
Tumors derived from the same tissue exhibit considerable
variability in their spectrum of mutations (Figure 2 and [7]).
The number and type of mutations observed is the result of
the size of the population at risk, the mutation rate, and the
microenvironment of the evolving clone. The individual
mutation rate can vary signiﬁcantly due to genetic [27,30] and
environmental effects (e.g., dietary fat intake, colonic
bacterial ﬂora, prior genotoxic therapy) [31,32]. These
factors, expected to be different for every tumor, also
contribute to the diversity of the mutational landscapes
observed in tumors. It is also worth noting that the number of
potential driver genes is likely to be an underestimate
because the power of the Sjo ¨blom et al. study to detect
infrequent mutations was limited [7]. The study of larger
numbers of tumors is likely to show that a few hundred
different genes may function as drivers. This increase in
potential drivers, however, will not have a substantial effect
on the conclusions of the models derived here (Equation 1).
Most tissues in metazoans undergo turnover and are
maintained by a population of tissue-speciﬁc stem cells that
generally replicate at a slow rate and exhibit properties such
as asymmetric division andi m m o r t a lD N As t r a n dc o -
segregation [33], perhaps to minimize the acquisition and
retention of mutations. Although many tumors have cancer
stem cells at their root [34] and colon cancer stem cells have
been reported [24,25], it is an open question whether such
cells arise solely due to the progressive accumulation of
mutations in normal stem cells or because cells can re-acquire
stem cell–like properties by mutation. The former scenario
would suggest a much smaller effective population size, an
important variable for modeling the evolution of cancer
[4,22,35–37]. The colon has approximately 10
7 crypts, each
one maintained by a small number of stem cells [27]. Initially,
these stem cells constitute the overall population at risk, but
the vast majority of patients with colon cancer develop
tumors as the natural progression of mucosal adenomas [38].
Thus, adenoma formation can be regarded as a mechanism by
which the population of cells at risk is increased and hence
the probability of cancer in patients with multiple adenomas
is dramatically increased. This is observed in familial
adenomatous polyposis patients, who have inherited muta-
tions of the APC gene.
Our model permits investigation of the impact of the
relevant parameters of tumor evolution on a global scale.
These parameters include the size of the population at risk,
the mutation rate, and the ﬁtness advantage conferred by
speciﬁc mutations (Equation 1). The model suggests that the
average waiting time for the appearance of the tumor is
strongly affected by the ﬁtness, s, conferred by the mutations,
with the average waiting time decreasing roughly as 1/s
(Figure S2). The mutation rate and the size of the population
at risk contribute only logarithmically to the waiting time and
hence have a weaker impact. Thus, the model of cancer
progression presented here might add to the debate whether
Figure 4. The Probability of Developing Cancer, Defined as the Occurrence of a Cell with Any 20 Mutated Genes Out of 100
Simulation results are displayed for three different population sizes (10
9, solid lines; 10
7, dashed lines; 10
5, dotted lines), three different selection
coefficients (10%, red lines; 1%, green lines; 0.1%, blue lines), and two different mutation rates (10
 7, top; 10
 5, bottom).
doi:10.1371/journal.pcbi.0030225.g004
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Genetic Progression of Cancerselection [10,11] or mutation [39] is the dominant force in
tumor development.
Finally, this model helps answer several questions about
colorectal tumorigenesis that have long perplexed research-
ers and clinicians. Why is there so much heterogeneity in the
times required for tumor progression among different
patients? Why is there so much heterogeneity in the sizes
and development times of tumors even within individual
patients, such as those with familial adenomatous polyposis, if
they all have the same initiating APC mutation? Why do
cancers behave so differently with respect to their response to
chemotherapeutic agents or radiation or their propensity to
metastasize? Our model is compatible with the view that a few
major mutational pathways, such as those involving APC, K-
ras, and p53, endow relatively large increases in ﬁtness that
can allow tumors to grow to sizes compatible with further
progression (Figure 5). However, the ﬁnal course to malig-
nancy will be determined by multiple mutations, each with a
small and distinct ﬁtness advantage, and these mutations
occur stochastically. Every cancer will thereby be dependent
on a unique complement of mutations that will determine its
propensity to invade, its ability to metastasize, and its
resistance to therapies. If this model is correct, then
biological heterogeneity is a direct consequence of the
tumorigenic process itself.
In our view, there is no reason to think that this model, or
the data on which it was based, will be applicable only to
colorectal cancers. Indeed, Sjo ¨blom et al. [7] have identiﬁed
similar mutational patterns in breast cancers, even though
these tumors have completely different embryologic origins
and are associated with distinct biological properties and
predisposing factors. We therefore predict that the basic
features of our model, i.e., a large number of potential drivers
each of which contributes only a small ﬁtness advantage, will
apply to the progression of most common solid tumors. These
tumors include those of the stomach, pancreas, bladder, lung,
prostate, and kidney. It is unlikely that the model will apply to
tumors that appear to have shorter waiting times, such as
leukemias and lymphomas.
After completion and submission of the manuscript, we
have learnt about related work recently published or being
published [40–42]. These independent papers, which build on
previous work published in [43], discuss a closely related
mathematical model. In contrast to our work, these excellent
contributions do not consider applications to the somatic
evolution of cancer. Furthermore, we arrive at similar
conclusions regarding the expected waiting time with a much
more concise method than used in the other papers. We are
grateful to Eric Brunet for bringing these references to our
attention.
Methods
Data. The collection of tumor data has been described in [7].
Brieﬂy, ;13,000 genes were sequenced from cancers of 11 patients
with advanced colorectal cancers. Any mutant gene detected in this
study was analyzed in an additional 24 patients with advanced
cancers. Tumors with mismatch repair (MMR) deﬁciency were not
included in this cohort, as MMR is known to increase the mutation
rate by orders of magnitude and would complicate the analysis of
mutations. Mutations were found in 519 genes, and, of these, 105
genes were found to be mutated in at least two independent tumors.
Statistical analysis. To test for dependencies between mutated
genes, we calculated all 3,003 pairwise partial correlations between
the 78 genes that were considered candidate drivers. Because the
number of observed tumors is much smaller than the number of
genes, we used the shrinkage method introduced in [44] for
estimation.
Wright-Fisher process. We initially consider a colonic adenoma
composed of 10
6 cells (;1m m
3) that is growing exponentially to
reach a size of 10
9 cells (;1c m
3). Serial radiological observations
show that the growth of unresected colonic adenomas is well-
approximated by an exponential function [45]. The average growth
rate determined in [45] implies that it takes ;11 years for an
adenoma to grow from 10
6 to 10
9 cells. We consider an evolving cell
population of size N(t) in generation t. Population growth is modeled
by assuming that growth is proportional to the average ﬁtness hwi of
the population, N(t þ 1) – N(t) ¼ a hwi N(t), where a is a constant
ensuring the experimentally observed growth dynamics, and N(0) ¼
10
6. Although hwi changes slightly over time, the growth kinetics is
still approximately exponential.
Each cell is represented by its genotype, which is a binary string of
length d ¼ 100 corresponding to the 100 potential driver genes. The
population is initially homogeneous and composed of wild-type cells
which are represented by the all-zeros string. In each generation, N(t)
genotypes are sampled with replacement from the previous gener-
ation. For large population sizes of 10
9 cells, it is not feasible to track
the fate of each of the possible 2
100 mutants in computer simulations.
However, we are interested in the ﬁrst appearance of any k-fold
mutant in the system (k ¼ 20). Thus, it sufﬁces to trace the k þ 1
mutant error classes, i.e., the number of j-fold mutants Nj(t) for each j
¼ 0, ..., k, in each generation. With every additional mutation, we
associate a selective advantage s. Thus, the relative ﬁtness of a j-fold
mutant is wj ¼ð 1 þ sÞ
j=
X k
‘¼0
ð1 þ sÞ
‘x‘, where xi¼Ni /N , and the average
population ﬁtness is hwi¼
X k
j¼0
xjwj. Ignoring back mutation, the
probability of sampling a j-fold mutant is
hj ¼
X j
i¼0
d   i
j   i
  
u j ið1   uÞ
d jwixiðtÞ;
where u is the mutation rate per gene. In each generation, the
population is updated by sampling from the multinomial distribution
Figure 5. Level Curves of Identical Cancer Dynamics
Each curve connects points in parameter space (x-axis: selective
advantage s, y-axis: population size N) with the same evolutionary
outcome, namely a 10% chance of developing a k-fold mutant after 8.2
years (or 3,000 generations). The mutation rate is 10
 7 (solid lines) and
10
 5 (dashed lines), respectively. Curves are labeled with the number k of
mutated genes that defines the cancer phenotype.
doi:10.1371/journal.pcbi.0030225.g005
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NðtÞ!
N0ðtÞ!   :::   NkðtÞ!
Y k
j¼0
h
NjðtÞ
j ;
where N(t) follows the above growth kinetics.
We use the discrete Wright-Fisher process rather than the
continuous Moran process [26], which might seem more natural for
cancer progression, because the Wright-Fisher process allows for
efﬁcient computer simulations even for very large population sizes.
Both models behave similarly for large population sizes [26].
Analytical approximation. The large cell population size might
suggest that one could consider a replicator equation in the limit as N
!‘.However,thisapproachyieldsaPoissondistributionforthetime-
dependent relative frequencies xj(t) with parameter k ¼ ud(e
st   1) / s,
implying that the variance of x increases over time, which contrasts
with the simulation results (Figure 3). The reason for this discrepancy
is that, in the replicator equation, higher-order mutants with high
ﬁtness are instantaneously generated. Thus, the time for their
expansion is underestimated compared to the waiting time in the
stochastic system. See Protocol S1 for further discussion of this
phenomenon.
To account for the stochastic ﬂuctuations in the accumulation of
k mutations, we model this process by decoupling mutation and
selection (see Protocol S1 for mathematical details). Brieﬂy, we
assume that j-fold mutants are generated at a constant rate with
increasing j. The Gaussian describing the distribution of mutant
error classes has mean vt, variance r
2, and travels with velocity v ¼
sr
2 (Figure 3). To determine v, we consider an (initially) exponen-
tially growing subpopulation of j-fold mutants and calculate the
expected time until one ( j þ 1)-mutant is produced. This leads to
v ¼ 2slogN= log s
ud
   2, and for constant population size N, we obtain
the approximation tk ’k log s
ud
   2=2slogN for the expected time to
the ﬁrst appearance of any k-fold mutant. The same waiting time in
a population growing exponentially from initial size Ninit ¼ N(0) to
ﬁnal size Nﬁn ¼ N(tk) is equal to that in a constant population with
effective population size N ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
NinitNfin
p
. Thus the speed of the
mutant wave in the growing population can be approximated by the
average of the values corresponding to the initial and ﬁnal
population sizes. This leads to tk ’k log s
ud
   2=slogðNinitNfinÞ for the
waiting time in a population growing from Ninit to Nﬁn. We will
often restrict our attention to constant population sizes because of
the equivalent waiting time in a constant population with effective
size equal to the geometric mean of the initial and ﬁnal population
sizes.
Supporting Information
Figure S1. Histogram of 3003 ¼ 78
2
  
Partial Correlations between
All 78 Cancer-Associated Genes
Correlation coefﬁcients have been computed from the 0/1 matrix
displayed in Figure 2.
Found at doi:10.1371/journal.pcbi.0030225.sg001 (5 KB PDF).
Figure S2. Time Tk until, in 10% of Patients, k Genes Are Mutated
The waiting time Tk (y-axis) is plotted versus the number k of mutated
genes (x-axis). Left panels correspond to a normal mutation rate of u
¼ 10
 7, right panels to an increased mutation rate of u ¼ 10
 5.
Population sizes of 10
5 (top panels), 10
7 (middle panels), and 10
9
(bottom panels) are considered. The selective advantage per mutation
varies among 0.1 (red lines), 0.01 (green), 0.001 (cyan), and 0 (purple).
Found at doi:10.1371/journal.pcbi.0030225.sg002 (11 KB PDF).
Protocol S1. PDF Document Entitled ‘‘Analytical Approximation for
the Expected Waiting Time’’ Which Contains the Mathematical
Details of the Model
Found at doi:10.1371/journal.pcbi.0030225.sd001 (152 KB PDF).
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